Xuesong Guan

TL;DR: Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.

TL;DR: Although this study was limited by a 2-week duration of exposure, data demonstrate that, exenatide had a greater effect than sitagliptin to lower postprandial glucose and a more potent effect to increase insulin secretion and reduce insulin secretion in T2D patients.

TL;DR: In patients with T2DM, adjunctive exenatide treatment for 2 years was generally well tolerated and resulted in a sustained reduction of HbA(1c), progressive reduction in weight, and improvements in HOMA-B, blood pressure, and the hepatic injury biomarkers, AST and ALT.

TL;DR: Exen atide twice-daily monotherapy resulted in glycemic improvements and reductions in body weight comparable to that of exenatide combination therapy with metformin in patients with type 2 diabetes.

TL;DR: In these adolescent patients with T2DM, administration of single 2.5- and 5-microg doses of exen atide were associated with dose-dependent increases in plasma exenatide concentrations and improved postprandial glucose concentrations compared with placebo.